Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.

Hong Liu | Xinwei Kuang | Yongchang Zhang | Youqiong Ye | Jialu Li | Long Liang | Zuozhong Xie | Liang Weng | Jia Guo | Hui Li | Fangyu Ma | Xiaodan Chen | Shuang Zhao | Juan Su | Nong Yang | Fang Fang | Yang Xie | Juan Tao | Jianglin Zhang | Mingliang Chen | Cong Peng | Lunquan Sun | Xin Zhang | Jing Liu | Leng Han | Xiaowei Xu | Mien-Chie Hung | Xiang Chen
Cancer cell | 2020

Here, we show that tumor ADORA1 deletion suppresses cell growth in human melanoma cell lines in vitro and tumor development in vivo in immune-deficient xenografts. However, this deletion induces the upregulation of PD-L1 levels, which inactivates cocultured T cells in vitro, compromises anti-tumor immunity in vivo, and reduces anti-tumor efficacy in an immune-competent mouse model. Functionally, PD-1 mAb treatment enhances the efficacy of ADORA1-deficient or ADORA1 antagonist-treated melanoma and NSCLC immune-competent mouse models. Mechanistically, we identify ATF3 as the factor transcriptionally upregulating PD-L1 expression. Tumor ATF3 deletion improves the effect of ADORA1 antagonist treatment of melanoma and NSCLC xenografts. We observe higher ADORA1, lower ATF3, and lower PD-L1 expression levels in tumor tissues from nonresponders among PD-1 mAb-treated NSCLC patients.

Pubmed ID: 32183950

Antibodies used in this publication

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Bio X Cell (tool)

RRID:SCR_004997

Commercial supplier and developer of in vivo antibodies. Provides antibodies and antibody production services.

View all literature mentions

NU/J (tool)

RRID:IMSR_JAX:002019

Mus musculus with name NU/J from IMSR.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

HEK293-FT (tool)

RRID:CVCL_6911

Cell line HEK293-FT is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (antibody)

RRID:AB_2315112

This monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

View all literature mentions

InVivoPlus anti-mouse CD8α (antibody)

RRID:AB_10950145

This monoclonal targets CD8α

View all literature mentions

PD-L1/CD274 antibody (antibody)

RRID:AB_2756526

This monoclonal targets PD-L1/CD274

View all literature mentions

Akt (pan) (C67E7) Rabbit mAb (antibody)

RRID:AB_915783

This monoclonal targets Akt (pan) (C67E7) Rabbit mAb

View all literature mentions

Cy3-AffiniPure Goat Anti-Mouse IgG (H+L) (antibody)

RRID:AB_2338680

This unknown targets Mouse IgG (H+L)

View all literature mentions

Adenosine A1 Receptor antibody [EPR6179] (antibody)

RRID:AB_10974139

This monoclonal targets Adenosine A1 Receptor antibody [EPR6179]

View all literature mentions

p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (antibody)

RRID:AB_390779

This monoclonal targets p44/42 MAPK (Erk1/2)

View all literature mentions

GAPDH antibody (antibody)

RRID:AB_2107436

This monoclonal targets GAPDH

View all literature mentions

HRP Goat Anti-Mouse IgG (H+L) (antibody)

RRID:AB_2769851

This unknown targets IgG (H+L)

View all literature mentions

Cy3-AffiniPure Goat Anti-Rabbit IgG (H+L) (antibody)

RRID:AB_2338000

This unknown targets Rabbit IgG (H+L)

View all literature mentions

InVivoPlus anti-mouse PD-1 (CD279) (antibody)

RRID:AB_10949053

This monoclonal targets PD-1 (CD279)

View all literature mentions

FITC anti-human/mouse Granzyme B Recombinant (antibody)

RRID:AB_2687030

This recombinant monoclonal targets Granzyme B

View all literature mentions

anti-DDDDK-tag (antibody)

RRID:AB_11123930

This monoclonal targets anti-DDDDK-tag

View all literature mentions

Granzyme B antibody (antibody)

RRID:AB_304251

This polyclonal targets Granzyme B

View all literature mentions

APC anti-mouse CD3 (antibody)

RRID:AB_2561456

This monoclonal targets CD3

View all literature mentions

β-Actin Antibody (C4) (antibody)

RRID:AB_2714189

This monoclonal targets β-Actin

View all literature mentions

ATF-3 (D2Y5W) Rabbit mAb (antibody)

RRID:AB_2799039

This monoclonal targets ATF-3

View all literature mentions

InVivoPlus rat IgG2a isotype control (antibody)

RRID:AB_1107769

This isotype control targets Trinitrophenol

View all literature mentions

HRP Goat Anti-Rabbit IgG (H+L) (antibody)

RRID:AB_2769854

This unknown targets IgG (H+L)

View all literature mentions

rat IgG2b I sotype control (antibody)

RRID:AB_1107780

This isotype control targets KLH

View all literature mentions

Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb (antibody)

RRID:AB_2315049

This monoclonal targets Phospho-Akt (Ser473)

View all literature mentions

SK-MEL-28 (cell line)

RRID:CVCL_0526

Cell line SK-MEL-28 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

B16-F10 (cell line)

RRID:CVCL_0159

Cell line B16-F10 is a Cancer cell line with a species of origin Mus musculus (Mouse)

View all literature mentions

LL/2 (LLC1) (cell line)

RRID:CVCL_4358

Cell line LL/2 (LLC1) is a Cancer cell line with a species of origin Mus musculus

View all literature mentions

A-375 (cell line)

RRID:CVCL_0132

Cell line A-375 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions